Skip navigation

From metabonomics to pharmacometabonomics: The role of metabolic profiling in personalized medicine

From metabonomics to pharmacometabonomics: The role of metabolic profiling in personalized medicine

Everett, Jeremy R. ORCID: 0000-0003-1550-4482 (2016) From metabonomics to pharmacometabonomics: The role of metabolic profiling in personalized medicine. Frontiers in Pharmacology, 7:297. ISSN 1663-9812 (doi:

PDF (Publisher's PDF)
15811_Everett_From metabonomics (pub PDF OA) 2016.pdf - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


Variable patient responses to drugs are a key issue for medicine and for drug discovery and development. Personalised medicine, that is the selection of medicines for subgroups of patients so as to maximise drug efficacy and minimise toxicity, is a key goal of 21st century healthcare. Currently, most personalised medicine paradigms rely on clinical judgement based on the patient’s history, and on the analysis of the patients’ genome to predict drug effects i.e. pharmacogenomics. However, variability in patient responses to drugs is dependent upon many environmental factors to which human genomics is essentially blind. A new paradigm for predicting drug responses based on individual pre-dose metabolite profiles has emerged in the past decade: pharmacometabonomics, which is defined as ‘the prediction of the outcome (for example, efficacy or toxicity) of a drug or xenobiotic intervention in an individual based on a mathematical model of pre-intervention metabolite signatures’. The new pharmacometabonomics paradigm is complementary to pharmacogenomics but has the advantage of being sensitive to environmental as well as genomic factors. This review will chart the discovery and development of pharmacometabonomics, and provide examples of its current utility and possible future developments.

Item Type: Article
Additional Information: © 2016 Everett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Uncontrolled Keywords: Metabonomics; metabolomics; pharmacometabonomics; pharmacometabolomics; personalised medicine; metabolic profiling
Subjects: R Medicine > RS Pharmacy and materia medica
Faculty / Department / Research Group: Faculty of Engineering & Science
Faculty of Engineering & Science > Department of Pharmaceutical, Chemical & Environmental Sciences
Last Modified: 31 Aug 2017 11:58
Selected for GREAT 2016: None
Selected for GREAT 2017: None
Selected for GREAT 2018: None
Selected for GREAT 2019: None

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics